Idorsia Company Profile

Headquartered in Switzerland - a biotech-hub of Europe—Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of over 750 highly qualified specialists dedicated to realizing our ambitious targets, a fully functional research center, and a strong balance sheet—the ideal constellation to bringing R&D efforts to business success.

Financial overview		**Full-year 2018**
in CHF million, except EPS (CHF) and number of shares (million)	**US GAAP**	**Non-GAAP***
Revenues	61	61
Operating expenses	(432)	(399)
Operating income (loss)	(371)	(339)
Net income (loss)	(386)	(340)
Basic EPS	(3.10)	(2.72)
Basic weighted average number of shares	124.8	124.8
Diluted EPS	(3.10)	(2.72)
Diluted weighted average number of shares	124.8	124.8

The full financial statements can be found in the Financial Report available on our corporate website.

* Idorsia measures, reports and issues guidance on non-GAAP operating performance. Idorsia believes that these non-GAAP financial measurements more accurately reflect the underlying business performance and therefore provide useful supplementary information to investors. These non-GAAP measures are reported in addition to, not as a substitute for, US GAAP financial performance.

Share Information

Idorsia was incorporated in March 2017 and listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017.

Idorsia Ltd is part of the following indices: SPI, SPIEX, SXSLI, SXI Life Sciences, and SXI Bio+Medtech.

Idorsia is traded under the following symbols: Reuters IDIA.S / Bloomberg IDIA.

Company Strategy

We will develop Idorsia into one of Europe's leading biopharmaceutical companies, with a strong scientific core. We have identified five key strategic priorities to ensure the company's success over the first 5 years:

Deliver promising compounds
Idorsia aims to deliver at least three products to market with the potential to significantly change treatment options in their target disease, resulting in assets with major commercial potential.

Be there from bench to bedside
Idorsia aims to build a commercial organization to maximize the value of our innovations.

Become a sustainable company
Idorsia's highly qualified professionals aim to rapidly advance the development pipeline and commercial readiness, so as to bring Idorsia to profitability within 5 years.

Build a bright future
Idorsia aims to create a clinical development pipeline comprising assets with a sales potential of at least CHF 5 billion.

Utilize state-of-the-art technologies
Idorsia aims to increasingly utilize state-of-the-art technologies to aid discovery, development and commercialization of our innovative therapies.

Clinical Development Pipeline

Compound	Mechanism of Action	Target Indication	Status
ACT-541468	Dual orexin receptor antagonist	Insomnia	Phase 3
Aprocitentan*	Dual Endothelin receptor antagonist	Resistant hypertension management	Phase 3
Clazosentan**	Endothelin receptor antagonist	Vasospasm associated with aneurysmal subarachnoid hemorrhage (aSAH)	Phase 3
Lucerastat	Glucosylceramide synthase (GCS) inhibitor	Fabry disease	Phase 3
Cenerimod	$S1P_1$ receptor modulator	Systemic lupus erythematosus	Phase 2
Selatogrel	P2Y12 receptor antagonis	Acute coronary syndrome (ACS)	Phase 2
ACT-774312	CRTH2 receptor antagonist	Nasal polyposis	Phase 2
ACT-519276	GBA2/GCS inhibitor	Orphan CNS disease	Phase 1
ACT-539313	Selective orexin 1 receptor antagonist	Anxiety	Phase 1
ACT-709478	T-type calcium channel blocker	Epilepsy	Phase 1

* In collaboration with Janssen Biotech to jointly develop and solely commercialize aprocitentan worldwide.
** Market registration trials are being conducted in Japan.

Partnerships

Collaboration Agreement with Janssen Biotech

In December 2017, Janssen Biotech, Inc. entered into a collaboration agreement with Idorsia to jointly develop and commercialize aprocitentan and any of its derivative compounds or products.

Idorsia received a one-time milestone payment of USD 230 million. Both parties have joint development rights over aprocitentan. Idorsia will oversee the Phase 3 development and regulatory submission for the treatment of patients with hypertension that is not controlled by at least three therapies (called resistant hypertension in the medical community). The costs will be shared equally between both partners. Janssen will oversee the Phase 3 development and submission for any additional indications.

Collaboration Agreement with Roche

In December 2017, Idorsia entered into a research collaboration that provides Roche with an exclusive option right to develop and market first-in-class compounds for a promising new approach in the field of cancer immunotherapy. Roche has paid Idorsia an upfront payment of CHF 15 million and has the option to exclusively license Idorsia compounds and compounds resulting from the collaboration, for a further payment of CHF 35 million, after a pre-determined period. After the exercise of its option right, Roche would have the exclusive worldwide right to develop and commercialize the Idorsia and collaboration compounds. Idorsia will be eligible to receive one-time development and regulatory milestones of up to CHF 410 million. Idorsia will also be entitled to one-time milestones based on sales thresholds, as well as tiered royalties on annual net sales of all products resulting from the collaboration.

Revenue Sharing Agreement with Johnson & Johnson

Idorsia Pharmaceuticals Ltd, J&J and Actelion Pharmaceuticals Ltd have entered into a Revenue Sharing Agreement in respect to ponesimod. Under the terms of the revenue sharing agreement, Idorsia Pharmaceuticals Ltd is entitled to receive quarterly payments of 8% of the net sales of ponesimod products from Actelion Pharmaceuticals Ltd.

Further Collaborations

Idorsia also has agreements in place with ReveraGen Inc., Santhera Pharmaceuticals, and Vaxxilon. For more information visit our corporate website.

Company milestones

2017

March
Incorporation of Idorsia

June
Listing of Idorsia on SIX

July
Positive results of Phase 2 program with ACT-541468 (DORA) in insomnia

December
Collaboration Agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan

December
Research collaboration agreement with Roche in the field of cancer immunotherapy

2018

May
Phase 3 registration study with lucerastat for patients with Fabry disease initiated

June
Phase 3 registration program with ACT-541468 for patients with insomnia initiated

June
Establishment of Idorsia pharmaceuticals Japan

June
Phase 3 registration study with aprocitentan for resistant hypertension management initiated

December
Simon Jose joined the company as Chief Commercial Officer

December
Multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus initiated

2019

February
Phase 3 registration program with clazosentan for patients with cerebral vasospasm associated with aSAH initiated

Idorsia is an independent biopharmaceutical company based on science and innovation. The company is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. It is headquartered in Allschwil/Basel, Switzerland and is quoted on the SIX Swiss Exchange (tickersymbol: IDIA). All trademarks are legally protected by their respective owners.

Disclaimer This fact sheet has the sole purpose to provide members of the public with general information about the activities of Idorsia. The forward-looking statements in this fact sheet are based on current expectations and belief of company management, which are subject to numerous risks and uncertainties.

Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil
Switzerland

investor.relations@idorsia.com
Phone +41 58 844 10 10
www.idorsia.com



Company Profile

Latest update:
February 2019